Aug 08, 2024 / 08:00AM GMT
Riad Mishlawi - Hikma Pharmaceuticals PLC - Chief Executive Officer, Executive Director
Okay, good morning, everyone. It's always great to sit in front of you when we have good results. It makes the day much more pleasing. Anyways, I just wanted to go over some, maybe, overall messages. We had, as you all know, we had an excellent performance in H1. Revenue was increased by about 10%, with the three businesses performing well, underpinned by our strong commercial and operational capabilities.
We continued to invest in the businesses and deliver on our corporate strategy. In the first half, we had grown our portfolio, launching 59 products across our businesses, and continued to strengthen our pipeline with more than 300 products currently in the pipeline.
We further strengthened our leadership team. As you know, we had some additions, we had some shuffling around and some changes in responsibilities. We announced strategic acquisitions of Xellia products. The Xellia acquisition included products, manufacturing facility and R&D assets. Of course, as you know, we're still waiting for
Half Year 2024 Hikma Pharmaceuticals PLC Earnings Call Transcript
Aug 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers